Vijaya Diagnost. (VIJAYA)
StalwartFairStock Score: 57/100 — STEADY
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹1,474.1 |
| Market Cap | ₹15,182.89 Cr |
| P/E Ratio | 81.31 |
| ROCE | 20.91% |
| ROE | 20.07% |
| Dividend Yield | 0.14% |
| Profit Growth | 37.3% |
| Debt/Equity | 0.44 |
| Sales Growth | 22.8% |
| Free Cash Flow | ₹42.6 Cr |
| Promoter Holding | 52.6% |
| 52-Week Range | ₹848 — ₹1,592 |
| Sector | Healthcare Services |
| Book Value | ₹93.06 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
As a value investor, I first ask: what does this business yield in cash and earnings, and at what price? Vijaya Diagnost grows well—sales up 19.44%, profit up 17.69%, latest quarter ₹205 Cr sales and ₹43 Cr net profit. ROE 20.07% and ROCE 20.91% show decent capital allocation, and Piotroski F-Score 8/9 suggests solid fundamentals. Debt/equity 0.40 and Altman Z 6.89 reassure me the balance sheet isn't dangerous. Promoter holding 52.60% is helpful. But here is the problem: I am a buyer at a price, not of a good story alone. At ₹1029.50, the market cap is ₹10,336 Cr, which is 64.42 times earnings. The DCF value given is ₹190.21, Graham Number ₹164.86, and the margin of safety is -509%. I cannot call that an investment; it is speculation. EV/EBITDA 94.32 is far beyond any margin of safety. Dividend yield 0.20% means I am paid almost nothing while waiting. Free cash flow of ₹43 Cr against a ₹10,336 Cr market cap gives a microscopic FCF yield. Even a fast grower must eventually justify price with cash profits; at 64 times earnings, Mr. Market expects perfection for many years. Growth of 17.69% is excellent, but it does not support such a valuation. If this were a private business, would I pay 64 times earnings? No. Graham taught me to weigh the margin of safety; here it is negative, not just absent. The score of 44/100 mixed seems fair—the business is okay, but the price is not. I will keep it on a watch list, not in my portfolio. If the market offers a significantly lower price, or if earnings grow into the valuation over many years, I might reconsider. For now, discipline requires walking away.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer